Research Article Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/genetics.1.001

Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan

  • 1Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children, Kabul, Afghanistan
  • 2Department of Hemato-oncology, Jumhoriat Hospital, Kabul, Afghanistan
  • 3Department of Medicine, Rabia Balkhi Hospital, Kabul, Afghanistan
  • 4Department of Pediatrics, French Medical Institute for Mothers and Children, Kabul, Afghanistan
  • 5Department of Hemato-oncology, Amiri Medical Complex, Kabul, Afghanistan
  • 6Department of Pathology and Laboratory Medicine, Agha Khan University Hospital, Karachi, Pakistan
+ Affiliations - Affiliations

Corresponding Author

Ahmed Maseh Haidary, ahmed.maseh9t9@gmail.com

Received Date: September 27, 2021

Accepted Date: October 06, 2021


Background: Current guidelines for chronic myeloid leukemia (CML) management include utilization of both conventional cytogenetics as well as advance molecular analysis at diagnosis and while monitoring the therapy. The reason being the fact that karyotype analysis is one of the indispensable tools for identification of additional chromosomal abnormalities of prognostic significance. Methodology: We conducted a descriptive case-series study of 33 patients to demonstrate the profile of karyotype abnormalities in CML. Results: 75.7% of patients had a single Philadelphia chromosome (Ph), while in addition to Ph, one patient had t (11;17), one patient had t (7;14), one patient had 5q deletion, one patient had double Ph and one patient had a complex karyotype with 6q deletion, monosomy 11, monosomy 12 and marker chromosome. Two patients with pathognomonic clinical feature of CML had normal karyotype and thus were advised to proceed with further molecular studies, since they showed significant clinical improvement with tyrosine kinase inhibitor therapy. Conclusion: Detection of additional chromosomal abnormalities in CML patients is a key to identification of patients requiring advance therapeutic modalities other than the conventional tyrosine kinase targeting agents. This is true both at diagnosis as well as during the tyrosine kinase inhibitor therapy.


Karyotypic, Chronic myeloid leukaemia, Tertiary level, Afghanistan

Author Information X